CIALIS (tadalafil) by Eli Lilly and Company is phosphodiesterase 5 inhibitors [moa]. Approved for phosphodiesterase 5 inhibitor [epc]. First approved in 2003.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
CIALIS (tadalafil) is an oral phosphodiesterase 5 (PDE5) inhibitor approved in 2003 for erectile dysfunction and benign prostatic hyperplasia. It works by relaxing smooth muscle and increasing blood flow to affected tissues. The drug is available in tablet form and represents a mature, well-established therapeutic option in the PDE5 inhibitor class.
As LOE approaches, the brand team is transitioning from growth-focused activities to life-cycle extension and cost-management strategies, likely with reduced headcount and budget reallocation.
Phosphodiesterase 5 Inhibitors
Phosphodiesterase 5 Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)
Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation
Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis
Actual Use Trial of Tadalafil 5 mg
Impact of Dental Desensitization Facilitated by a Child Life Specialist Distress and Cooperation
Worked on CIALIS at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPositions in CIALIS-focused roles offer stability and established market knowledge but limited growth trajectory as the product approaches and enters loss-of-exclusivity. Career progression on this product is best suited for professionals seeking mature-market expertise, cost-containment strategies, or transition toward generic/biosimilar oversight rather than innovation-driven advancement.